Resverlogix management commentary cites higher finance costs as nine-month 2026 net loss widens

PUBT · 1d ago
Resverlogix management commentary cites higher finance costs as nine-month 2026 net loss widens
  • Resverlogix management, in its commentary, reported third-quarter 2026 net loss of USD 793,000 versus USD 951,000 a year earlier.
  • Expenses rose to USD 1.62 million from USD 1.13 million, with higher clinical costs including the post-COVID conditions trial.
  • Finance income increased to USD 829,000 from USD 185,000, offsetting higher expenses.
  • Nine-month net loss widened to USD 10.33 million from USD 7.56 million, reflecting higher finance costs and operating expenses.
  • Management warned cash of USD 200,000 at September 30 was insufficient for commitments; failure to raise capital could force operations to cease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Resverlogix Corporation published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.